U.S. Polo Assn. Announces His Highness Maharaja Sawai Padmanabh Singh of Jaipur, India, as New Global Brand Ambassador

WEST PALM BEACH, FL / ACCESSWIRE / February 20, 2024 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), has announced His Highness Maharaja Sawai Padmanabh Singh(Pacho) of Jaipur, India, as its new Global Brand Ambassador.

Sawai Padmanabh Singh is a member of the Royal Family of Jaipur and is the current Maharaja of Jaipur. A professional polo player, Singh has played for and captained the Indian National Team and has participated in tournaments across Argentina, Australia, Brazil, Canada, Chile, France, Germany, Spain, Thailand, the United Kingdom, the United States and more.

Pacho’s passion and enthusiasm for the sport of polo has helped popularize it beyond the field, and today the tournaments in Jaipur draw visitors from around the world. With the royal patronage of the Rajasthan Polo Club, Singh continues to further the cause of supporting this unique and historic sport.

"It’s an honor to be selected as Global Brand Ambassador for U.S. Polo Assn., a brand that is so popular and respected in my home country of India and so authentic to the sport of polo," said His Highness, Padmanabh Singh, Maharaja of Jaipur. "I look forward to representing the brand with great enthusiasm at sporting and fashion events and on social media for fans and consumers around the world!"

The Role of a U.S. Polo Assn. Global Brand Ambassador

The scope of Pacho’s role as Global Brand Ambassador is broad and designed to shine the spotlight on talented polo players and the authenticity of the brand around the world. He will be outfitted in U.S. Polo Assn. apparel and performance gear both on and off the field, share his polo-related and other daily activities on social media, participate in sporting and fashion events on behalf of U.S. Polo Assn., as well as engage in media requests for interviews and campaigns.

"U.S. Polo Assn. is proud to welcome Pacho to our outstanding roster of Global Brand Ambassadors," said J. Michael Prince, President and CEO of USPA Global, which manages the multi-billion-dollar U.S. Polo Assn. brand. "U.S. Polo Assn. is a brand that spans 190 countries, including more than 400 brand stores in India alone, and Pacho is a perfect representative of a global polo player that encompasses what our sport-inspired brand is all about – global, vibrant, authentic, and exciting."

U.S. Polo Assn. will also launch a Capsule Collection of elevated polo shirts, white sports pants, oxfords, and sport-inspired accessories inspired by Pacho that he will promote as a U.S. Polo Assn. Global Brand Ambassador.

His Highness Maharaja Sawai Padmanabh Singh and the Sport of Polo

His Highness brings to U.S. Polo Assn. his spirit of sportsmanship and distinctive style that he displays both on and off the field.

Pacho is passionate about the sport of polo and has represented India in the sport across the world. He was named Captain of the Indian National Polo Team in 2022. His journey began while he was at school in the U.K., where he joined the prestigious Guards Polo Club and played at different levels in the U.K. He has won almost every major polo tournament in India and was also the youngest player to win the India Open.

He is also working towards promoting polo in Jaipur through various initiatives like high-goal tournaments, Ladies’ Polo, and Junior Polo. He has recently revived the historic Jaipur Polo Team to keep the rich legacy of his family’s contributions to the sport alive. The Jaipur Polo Team was revered as one of the greatest in the world and reigned supreme during its time, winning every major polo tournament including the World Cup in 1957 at Deauville, France.

As patron of the Rajasthan Polo Club, Pacho has instituted various training programs for young sportspersons to enable them to learn riding and polo at very nominal rates, with special programs for girls. It is also thanks to Pacho’s efforts that every polo season now includes low-goal tournaments, Ladies’ Polo, and Out of Hat series for aspiring young players to participate in, encouraging greater participation and inclusivity in a sport perceived by many as elitist. As a result, and unlike any other polo center, Jaipur sees polo fans from many different demographics rush to see and support the game. This is encouraged by His Highness through free access for all games organized at the polo club.

U.S. Polo Assn., an India Power Brand

U.S. Polo Assn.’s popularity in India has only grown with the population, making India prime to be the global brand’s fastest-growing market. The tremendous growth in popularity and ultimately market share is not without effort, which includes a strategy focused on both brick-and-mortar and e-commerce, as well as overall brand marketing through storytelling.

"We are thrilled to have His Highness, the Maharaja of Jaipur, as a Global Brand Ambassador for U.S. Polo Assn., one of the most important brands in India," said Shailesh Chaturvedi, Managing Director and CEO of Arvind Fashions Ltd. "Pacho’s stature, popularity, sportsmanship and passion are all an excellent representation of our global, sport-inspired brand."

"The combination of having His Highness as our Ambassador, alongside our new, iconic Legends Campaign, our exciting India website, as well as our revamped stores – it’s an incredible time for U.S. Polo Assn. consumers to be immersed in our unique brand story in India and around the world," added Chaturvedi.

As one of India’s leading casual wear power brands, the multi-billion-dollar, global, sport-inspired U.S. Polo Assn. brand has launched an exclusive brand-specific website USPoloAssn.in to further enhance digital offerings for customers and provide easier access to its product offerings. Its brick-and-mortar growth is exploding in India as well, with 100 more stores in the coming years.

Currently, the brand’s retail footprint in India is at more than 400 brand stores, and over 2,000 shop-in-shops, across more than 200 cities in India. Globally, the U.S. Polo Assn. brand is in 190 countries and has global retail sales of more than $2.5 billion.

About U.S. Polo Assn.

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the governing body for the sport of polo in the United States and one of the country’s oldest sports governing bodies, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through over 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. A recent, multi-year deal with ESPN to broadcast the premier polo championships in the world, sponsored by U.S. Polo Assn., has made the thrilling sport accessible to millions of households globally for the very first time.

U.S. Polo Assn. has consistently been named one of the top global sports licensors alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized around the world with awards for global growth, expansion, licensing, and digital presence. Due to its tremendous success as a global brand, particularly in the last five years, U.S. Polo Assn. has been featured in Forbes, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn. 

About Arvind

Arvind Fashions Ltd., based in Bengaluru, is India’s No. 1 casual and denim player in the country’s retail industry, a lifestyle powerhouse with a strong portfolio of fashion brands catering to consumers across various sub-categories and price points. With a host of renowned brands, both international and indigenous, like U.S. Polo Assn., ARROW, Tommy Hilfiger, Calvin Klein and Flying Machine, Arvind has a presence across lifestyle brands and value fashion. Visit Arvind, USPoloAssn.in, and follow @uspoloassnindia.

Contact Information

Stacey Kovalsky
VP Global PR and Communications
skovalsky@uspagl.com
+001.561.790.8036

Shannon Stilson
VP, Sports Marketing & Media
sstilson@uspagl.com
+001.561.227.6994

Deepansh Bhargava
Vice President, Marketing, U.S. Polo Assn. India at Arvind Fashions Limited
deepansh.bhargava@arvindbrands.co.in
+91 9343897011

SOURCE: USPA Global Licensing Inc.

.

View the original press release on newswire.com.

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

Hyris’ molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns.

LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three or less hours after capture. Current approaches can take up to six months since samples must be collected in remote areas and then transported to centralized laboratories for testing.

Hyris fights malaria
Hyris fights malaria
Disease vector mosquito

The early and cost-effective detection of mosquito resistance to insecticides is essential for planning and implementing effective malaria control strategies. Mosquito-killing insecticides remain key weapons in preventing malaria transmission in sub-Saharan Africa and other malaria-endemic parts of the world. However, mosquitoes often develop resistance to insecticides, rendering them ineffective in disrupting the spread of the disease.

The research team is led by Professor George Dimopoulos at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Malaria Research Institute, and together with Professor Charles Wondji at the Centre for Research in Infectious Diseases in Yaoundé, Cameroon the team has been working since 2021 conducting laboratory R&D, and field testing in malaria-endemic areas of Cameroon. This is enabled by the distinctive features of the Hyris System™ for molecular testing that is based on a simple portable battery-powered device rather than a heavy laboratory-based benchtop machine.

The newly developed Hyris technology of pre-filled dried cartridges enables running the diagnostic assay by simply adding the mosquito sample to a well already containing all other reagents, simplifying the testing workflow. The stability of the dried reagents enables their storage at room temperature for up to six months thereby not requiring freezers which are lacking at most sample collection sites in the field.

This research project was supported by a Bill & Melinda Gates Foundation grant made to Johns Hopkins University.

"This new test is deployable right in-field," explains Lorenzo Colombo, CTO and Managing Director at Hyris. "Our technology enables researchers to collect a mosquito sample in the field and conduct the molecular diagnostic assay right there, with real-time acquisition, from a central lab, of insecticide resistance data from the disease-endemic area."

The team is currently exploring the path for nationwide deployment of the mosquito insecticide resistance surveillance system in Cameroon, something that would enable real-time informed decision-making on malaria mosquito control campaigns using the most effective insecticides.

Stefano Lo Priore, Founder and CEO at Hyris, further explains the advantages of this new test: "The necessity of cold chain has always been a critical roadblock for any test distribution in remote areas. This new malaria mosquito insecticide resistance test does not require any cold chain for shipping, making it one hundred percent field-deployable." Lo Priore also highlights how such projects perfectly align with Hyris’ commitment to developing advanced biotech solutions for critical environments. "We work to provide increasingly efficient ways to manage outbreak readiness and health prevention, especially in the most challenging situations."

For more information, feel free to contact a Hyris specialist at info@hyris.net.

Contact Information

Gabriele Salaris
Global Experience Manager
gabriele.salaris@hyris.net
+39 345 555 3379

SOURCE: Hyris Ltd

.

View the original press release on newswire.com.

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

Hyris’ molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns.

LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three or less hours after capture. Current approaches can take up to six months since samples must be collected in remote areas and then transported to centralized laboratories for testing.

Hyris fights malaria
Hyris fights malaria
Disease vector mosquito

The early and cost-effective detection of mosquito resistance to insecticides is essential for planning and implementing effective malaria control strategies. Mosquito-killing insecticides remain key weapons in preventing malaria transmission in sub-Saharan Africa and other malaria-endemic parts of the world. However, mosquitoes often develop resistance to insecticides, rendering them ineffective in disrupting the spread of the disease.

The research team is led by Professor George Dimopoulos at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Malaria Research Institute, and together with Professor Charles Wondji at the Centre for Research in Infectious Diseases in Yaoundé, Cameroon the team has been working since 2021 conducting laboratory R&D, and field testing in malaria-endemic areas of Cameroon. This is enabled by the distinctive features of the Hyris System™ for molecular testing that is based on a simple portable battery-powered device rather than a heavy laboratory-based benchtop machine.

The newly developed Hyris technology of pre-filled dried cartridges enables running the diagnostic assay by simply adding the mosquito sample to a well already containing all other reagents, simplifying the testing workflow. The stability of the dried reagents enables their storage at room temperature for up to six months thereby not requiring freezers which are lacking at most sample collection sites in the field.

This research project was supported by a Bill & Melinda Gates Foundation grant made to Johns Hopkins University.

"This new test is deployable right in-field," explains Lorenzo Colombo, CTO and Managing Director at Hyris. "Our technology enables researchers to collect a mosquito sample in the field and conduct the molecular diagnostic assay right there, with real-time acquisition, from a central lab, of insecticide resistance data from the disease-endemic area."

The team is currently exploring the path for nationwide deployment of the mosquito insecticide resistance surveillance system in Cameroon, something that would enable real-time informed decision-making on malaria mosquito control campaigns using the most effective insecticides.

Stefano Lo Priore, Founder and CEO at Hyris, further explains the advantages of this new test: "The necessity of cold chain has always been a critical roadblock for any test distribution in remote areas. This new malaria mosquito insecticide resistance test does not require any cold chain for shipping, making it one hundred percent field-deployable." Lo Priore also highlights how such projects perfectly align with Hyris’ commitment to developing advanced biotech solutions for critical environments. "We work to provide increasingly efficient ways to manage outbreak readiness and health prevention, especially in the most challenging situations."

For more information, feel free to contact a Hyris specialist at info@hyris.net.

Contact Information

Gabriele Salaris
Global Experience Manager
gabriele.salaris@hyris.net
+39 345 555 3379

SOURCE: Hyris Ltd

.

View the original press release on newswire.com.

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

Hyris’ molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns.

LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three or less hours after capture. Current approaches can take up to six months since samples must be collected in remote areas and then transported to centralized laboratories for testing.

Hyris fights malaria
Hyris fights malaria
Disease vector mosquito

The early and cost-effective detection of mosquito resistance to insecticides is essential for planning and implementing effective malaria control strategies. Mosquito-killing insecticides remain key weapons in preventing malaria transmission in sub-Saharan Africa and other malaria-endemic parts of the world. However, mosquitoes often develop resistance to insecticides, rendering them ineffective in disrupting the spread of the disease.

The research team is led by Professor George Dimopoulos at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Malaria Research Institute, and together with Professor Charles Wondji at the Centre for Research in Infectious Diseases in Yaoundé, Cameroon the team has been working since 2021 conducting laboratory R&D, and field testing in malaria-endemic areas of Cameroon. This is enabled by the distinctive features of the Hyris System™ for molecular testing that is based on a simple portable battery-powered device rather than a heavy laboratory-based benchtop machine.

The newly developed Hyris technology of pre-filled dried cartridges enables running the diagnostic assay by simply adding the mosquito sample to a well already containing all other reagents, simplifying the testing workflow. The stability of the dried reagents enables their storage at room temperature for up to six months thereby not requiring freezers which are lacking at most sample collection sites in the field.

This research project was supported by a Bill & Melinda Gates Foundation grant made to Johns Hopkins University.

"This new test is deployable right in-field," explains Lorenzo Colombo, CTO and Managing Director at Hyris. "Our technology enables researchers to collect a mosquito sample in the field and conduct the molecular diagnostic assay right there, with real-time acquisition, from a central lab, of insecticide resistance data from the disease-endemic area."

The team is currently exploring the path for nationwide deployment of the mosquito insecticide resistance surveillance system in Cameroon, something that would enable real-time informed decision-making on malaria mosquito control campaigns using the most effective insecticides.

Stefano Lo Priore, Founder and CEO at Hyris, further explains the advantages of this new test: "The necessity of cold chain has always been a critical roadblock for any test distribution in remote areas. This new malaria mosquito insecticide resistance test does not require any cold chain for shipping, making it one hundred percent field-deployable." Lo Priore also highlights how such projects perfectly align with Hyris’ commitment to developing advanced biotech solutions for critical environments. "We work to provide increasingly efficient ways to manage outbreak readiness and health prevention, especially in the most challenging situations."

For more information, feel free to contact a Hyris specialist at info@hyris.net.

Contact Information

Gabriele Salaris
Global Experience Manager
gabriele.salaris@hyris.net
+39 345 555 3379

SOURCE: Hyris Ltd

.

View the original press release on newswire.com.

General Atomics Expands International Collaborations and Partnerships With Japan in Critical and Emerging Technologies

SAN DIEGO, CA / ACCESSWIRE / February 19, 2024 / General Atomics, a defense and diversified technologies company with affiliates operating on five continents, is expanding its collaborations and partnerships across Japan with new investments in the nuclear energy and rare earth elements sectors.

Numerous teaming arrangements are in the late stages of discussion and are set to be announced in early 2024. These partnerships will complement the company’s existing relationships as a long-term partner collaborating with Japanese industry and government agencies.

"General Atomics is committed to collaborating with its Japanese partners to advance the development of cutting-edge technologies in the maritime security, nuclear energy, and rare earth elements sectors," said Dr. Vivek Lall, chief executive at General Atomics Global Corporation. "Building on a legacy of successful collaborations, we have held a series of strategic engagements with government officials, industry leaders, and research institutions in Japan. These engagements have laid the foundation for future partnerships aimed at advancing the development of critical and emerging technologies."

In 2023, Japan’s Kyoto Fusioneering announced an agreement with GA to supply two advanced gyrotrons to the U.S. Department of Energy’s DIII-D National Fusion Facility in San Diego, California.

Currently, the Japan Coast Guard (JCG) and Japan Maritime Self-Defense Force (JMSDF) are testing and deploying the MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) built by General Atomics Aeronautical Systems, Inc. (GA-ASI). SeaGuardian is a long-endurance maritime surveillance aircraft that can be used for a variety of missions, including search and rescue, disaster response, and maritime law enforcement.

GA-ASI’s MQ-9B aircraft is revolutionizing the global RPA systems market by providing true all-weather capability and full compliance with STANAG-4671 (NATO UAS airworthiness standard). This feature, along with GA-ASI’s operationally proven collision avoidance radar, enables flexible operations in civil airspace.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.

For more information, visit www.ga-asi.com.

Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.

Contact Information

GA-ASI Media Relations
asi-mediarelations@ga-asi.com
+1 (858) 524-8101

SOURCE: General Atomics Aeronautical Systems, Inc.

.

View the original press release on newswire.com.

King Faisal Specialist Hospital & Research Centre ยืนหยัดมั่นคงในฐานะผู้นำด้านการดูแลสุขภาพระดับโลกและระดับภูมิภาค

เมืองริยาด, ประเทศซาอุดีอาระเบีย, Feb. 16, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) ครองตำแหน่งอีกครั้ง ซึ่งเป็นปีที่สองติดต่อกันในฐานะผู้นำระดับโลกด้านการดูแลสุขภาพ รวมถึงเป็นศูนย์อันดับหนึ่งในตะวันออกกลางและแอฟริกาที่ติดอันดับที่ 20 ของโลกในบรรดาสถาบันดูแลสุขภาพชั้นนำในรายงาน Brand Finance Global Top 250 Hospitals 2024 KFSH&RC ยังคงยืนหยัดเป็นองค์กรแถวหน้าทั้งในระดับท้องถิ่นและระดับภูมิภาค ตอกย้ำถึงความมุ่งมั่นในการส่งมอบนวัตกรรมทางการแพทย์และการดูแลสุขภาพที่มีผู้ป่วยเป็นศูนย์กลางในระดับโลก

โดยมี KFSH&RC เป็นหัวหอกร่วมด้วย King Saud Medical City, King Khalid University Hospital, National Guard Health Affairs และ King Fahd Medical City ซึ่งทุกแห่งล้วนติดอันดับสูงสุด 100 อันดับแรกของโลก รวมถึง King Fahd University Hospital และ King Abdullah Medical City ที่ติดอันดับระหว่าง 101 ถึง 250 ของโลก การประเมินอันดับนี้อิงตามข้อมูลเชิงลึกจากผู้ปฏิบัติงานด้านการดูแลสุขภาพหลายพันคนในกว่า 30 ประเทศ

ด้วยผลงานในการจัดอันดับระดับโลกที่โดดเด่นของ KFSH&RC นี้ย่อมถือเป็นเครื่องพิสูจน์ถึงเป้าหมายด้านการเปลี่ยนแปลงด้านการดูแลสุขภาพ และผลกระทบด้านการเปลี่ยนแปลงจาก Vision 2030 ของราชอาณาจักร ซึ่งเป็นผลจากการปรับปรุงบริการด้านการดูแลสุขภาพอย่างต่อเนื่อง รวมถึงการแสวงหาความก้าวหน้าทางเทคโนโลยีทั่วทั้งราชอาณาจักร เพื่อการก้าวขึ้นเป็นประเทศที่มีความเจริญรุ่งเรืองและประชาชนมีสุขภาพดี

Brand Finance ก่อตั้งขึ้นในปี 2539 ใช้ดัชนีชี้วัดประสิทธิภาพมากกว่า 30 รายการ ซึ่งครอบคลุมทั้งด้านการดูแลสุขภาพ ศูนย์วิจัย และการศึกษา ในการประเมินโรงพยาบาลมากกว่า 500 แห่งทั่วโลกเป็นประจำทุกปี เพื่อให้การสนับสนุนการตัดสินใจเชิงกลยุทธ์ตามวิทยาศาสตร์

King Faisal Specialist Hospital & Research Centre เป็นหนึ่งในผู้นำระดับโลกด้านการให้บริการดูแลสุขภาพเฉพาะทาง การขับเคลื่อนนวัตกรรม และการดำเนินการในฐานะศูนย์กลางการวิจัยและการศึกษาทางการแพทย์ขั้นสูง โรงพยาบาลมุ่งมั่นที่จะพัฒนาเทคโนโลยีทางการแพทย์ให้ก้าวหน้าและยกระดับมาตรฐานการดูแลสุขภาพทั่วโลกผ่านความร่วมมือเชิงกลยุทธ์กับสถาบันที่มีชื่อเสียงในระดับท้องถิ่น ภูมิภาค และนานาชาติ

เกี่ยวกับ King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) ถือเป็นสถาบันดูแลสุขภาพชั้นนำในตะวันออกกลาง โดยมีเจตจำนงที่จะเป็นทางเลือกที่ดีที่สุดสำหรับผู้ป่วยทุกรายที่กำลังต้องการการรักษาพยาบาลเฉพาะทาง โรงพยาบาลแห่งนี้มีประวัติอันยาวนานในการรักษาโรคมะเร็ง โรคหัวใจและหลอดเลือด การปลูกถ่ายอวัยวะ ประสาทวิทยาศาสตร์ และพันธุศาสตร์

ในปี 2567 “Brand Finance” ได้จัดอันดับให้ King Faisal Specialist Hospital & Research Center เป็นศูนย์วิชาการทางการแพทย์ชั้นนำในภูมิภาคตะวันออกกลางและแอฟริกา และติดหนึ่งใน 20 อันดับแรกของโลกด้วย นอกจากนี้ ในปี 2565 เรายังได้รับการยกย่องให้เป็นหนึ่งในผู้ให้บริการด้านการดูแลสุขภาพชั้นนำระดับโลกจากนิตยสาร Newsweek

มีการออกพระราชกฤษฎีกาเมื่อวันที่ 21 ธันวาคม 2564 ซึ่งเป็นส่วนหนึ่งของโครงการ Saudi Vision 2030 เพื่อปฏิรูปโรงพยาบาลให้เป็นองค์กรอิสระที่ไม่แสวงหาผลกำไรที่รัฐบาลเป็นเจ้าของ ซึ่งปูทางไปสู่โครงการปฏิรูปที่ครอบคลุมเพื่อบรรลุผลสำเร็จในการเป็นผู้นำระดับโลกด้านการดูแลสุขภาพผ่านความเป็นเลิศและนวัตกรรม

คุณสามารถรับชมรูปภาพประกอบของประกาศนี้ได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/1cab7add-5d3e-482c-bd5b-cc8856cf7875

ข้อมูลการติดต่อ 

หากต้องการทราบรายละเอียดเพิ่มเติม โปรดติดต่อ:

คุณ Essam Al-Zahrani รักษาการหัวหน้าฝ่ายกิจการสื่อ, 0555254429

คุณ Abdullah Al-Awn เจ้าหน้าที่ฝ่ายประสานงานสื่อ, 0556294232

GlobeNewswire Distribution ID 9038753